The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...

The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year injectable drug to be used for HIV ...

Lenacapavir is an antiretroviral medicine that helps prevent 99.9 per cent of all HIV transmission, according to studies.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Winnie Byanyima says her organization has lost almost 50% of its funding, a gap that is undermining global efforts to combat ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.

A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More pharmaceutical news is about Dupixent, GLP-1 results, and more.